Italy
Joined February 2019
- Tweets437
- Following183
- Followers590
- Likes409
Breast Cancer Academy retweeted
Elena Cecchettin, sorella di Giulia uccisa dall'ex fidanzato Filippo Turetta l'11 novembre 2023, ha continuato a fare rumore per Giulia e a gridare contro una cultura dove «nessun uomo è buono se non fa nulla per smantellare la società che li privilegia tanto». Il 12 maggio Elena sarà al Salone Internazionale del Libro di Torino con Alessandra Campani, socia fondatrice dell’associazione Nondasola, e Barbara Stefanelli, vicedirettrice vicaria del Corriere della Sera per incontrare le ragazze e i ragazzi. Qui potete inviarci le vostre domande per lei: ne discuteremo al Salone
27esimaora.corriere.it/24_ap…
Breast Cancer Academy retweeted
Very happy to see that our paper on @eBioMedicine is the Editor's pick from the April issue! B-cell immunity is finally gaining its spot in the onocoimmunology field. In this paper we show how it is associated with pCR and prognosis in TNBC ⬇️@prat_aleix @evomet_itn @fara_bm
Editor pick from April issue
@BenedettaConte5 @prat_aleix @fara_bm & coll
Identified a 14-gene immunoglobulin B-cell signature linked to improved prognosis and pathological complete response in patients with early-stage triple-negative breast cancer
Read bit.ly/4b7WpYM
On-line nuovi materiali!
📚Disponibili i materiali (PDF, video) del webinar di dicembre che ha presentato una selezione di lavori presentati all'ultimo San Antonio Breast Cancer Symposium.
tinyurl.com/56phrzhd
#breastcancer #SABCS23 #oncology
Breast Cancer Academy retweeted
🔬Breaking barriers in #TNBC Unleashing the power of #ADCs 👉🏼 doi.org/10.1016/j.ctrv.2023.… Thanks to Arianna Dri and the extraordinary group of coauthors @arpino_grazia
@BianchiniGP @curijoey
@MicheleDelauren @delmastro_lucia @alessandrafab11 @ALEDIGNUS12
@valeguarneri
Breast Cancer Academy retweeted
L’analisi di un gene potrà rivelare il periodo ideale di trattamento per minimizzare i rischi e amplificare i benefici in ogni donna colpita da tumore al seno positivo per i recettori ormonali.
Studio finanziato da @MinisteroSalute
Leggi di più 👇
ospedalesanmartino.it/it/ric…
@AACR
WEBINAR LIVE
Breast Cancer Academy: le novità da San Antonio
1,5 Crediti ECM | 18 dicembre 2023
ISCRIVITI ORA
tinyurl.com/2h88jhfm
#breastcancer #SABCS23 #oncology
Breast Cancer Academy retweeted
Honoured of presenting the first safety analysis of the GIM26 - TRASTHER study at the oral communication session of #AIOM23 congress.
Key topics: real world evidence, post-neoadjuvant T-DM1, safety data
@UniGenova @GIM @AIOMtweet
Breast Cancer Academy retweeted
We are so glad to share our immuno-genomic model for HR+/HER2- eBC based on the integrated evaluation of Recurrence Score & TILs.
💡Just out on European Journal of Cancer
@vitti10
doi.org/10.1016/j.ejca.2023.…
SNPs of aromatase could be useful e biomarkers to personalize both extended andjuvant endocrine treatment and survivorship intervention in patients with ER+ early #breastcancer . Validation needed!
⬇️⬇️⬇️⬇️⬇️
🚨🚨 Promising biomarker to select patients for extended adjuvant aromatase inhibitors in patients with #breastcancer 🚨🚨
Article out today in @CCR_AACR
open access
doi.org/10.1158/1078-0432.CC…
⬇ Thread follows @matteolambe @prat_aleix @OncoAlert @UniGenova @FrancescoSche20
Breast Cancer Academy retweeted
Happy to share at #ESMO23 our work (2239P) on gene signatures capturing tertiary lymphoid structures (TLS) from pts prescreened at @SOLTI ACROPOLI trial ➡️ 14-gene B-cell signature IGG strongly associated with TLS across cancer types! @prat_aleix @TomasPascualMD @hospitalclinic
Breast Cancer Academy retweeted
Si è concluso il 19th Meet The Professor | Advanced International Breast Cancer Course (AIBCC).
Un ringraziamento speciale va ai Resp. Scientifici Pierfranco Conte, Valentina Guarneri, Philip Poortmans e @prat_aleix Prat e ai membri del Comitato Scientifico Internazionale.
Breast Cancer Academy retweeted
Impact of the endocrine resistance/sensitivity classification according to consensus guidelines for advanced #BreastCancer
Findings provide evidence on prognostic and clinical impact of the currently adopted classification in HR+/HER2− advanced BC
bit.ly/3MQVul5
Is the definition of endocrine resistance/sensitivity in CTs really able to stratify prognosis of patients with HR+/HER2- #BC?
🗞️ Take a look of this individual patient-level analysis from 4 Gruppo Italiano Mammella (#GIM) studies (>6,000 pts) just published on @eClinicalMed
Breast Cancer Academy retweeted
Outstanding @fara_bm at #ESMOBreast23 on HER2/ERBB2 mRNA leves and response to HER3-DXd in @_SOLTI TOTHER3 trial
Lower ERBB2 👉better response from HER3-DXd
Biological explanation still unknown. Maybe the answer is the HER2-HER3 dimerization affecting HER3 stability?
Breast Cancer Academy retweeted
Jee Hyun Kim at #ESMOBreast23 on biomarker-driven strategies in HER2+ BC. Genomic biomarkers predict prognosis beyond clinical factors. Assays integrating both like #HER2DX can better guide tx. More evidence available at the poster display tomorrow at 12.15 @RevealGenomics
Breast Cancer Academy retweeted
Great talk by @prat_aleix on HR+/HER2 BC biomarkers. My fav part:
basal-like and immunogenic phenotypes can be found in HR+/HER2- too (even in ER>10%!), and are associated with 👎response to endocrine tp and 👍 response to chemo (and maybe IO) #ESMOBreast23 – at Berlin, Germany
Breast Cancer Academy retweeted
In case you missed it! 👉Landmark #POSITIVE study published in @NEJM by Dr. Ann Partridge and colleagues which helps us understand the impact of Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.
#breastcancer #bcsm #pregnancy
pubmed.ncbi.nlm.nih.gov/3713…
Breast Cancer Academy retweeted
HER2: bersaglio mobile? tinyurl.com/2kjksw4n
Breast Cancer Academy retweeted
One of the most thought provoking and brilliant works in the HER2-low space.
👉most patients with HER2-neg MBC simultaneously harbor both HER2-0 and HER2-low lesions, even within the same organ.
Congrats Tatjana Geukens & colleagues for the publication!
ejcancer.com/article/S0959-8…
Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancer
📌HER-Low and HER2-zero are present together in 80% of patients
📌Incompatibility is quite high even in different sampling sites of the same metastasis
❓️How should we identify patients for anti-HER2 ADCs
❓️Is a single negative biopsy sufficient?
❓️Can all HR-positive patients be considered HER-Low in the near future?
Kudos to the researchers for this great work👏
@OncBrothers @stolaney1 @curijoey @PTarantinoMD @UmutDisel @muratdincer7 @BijoyTelivala @PathologyPat
@DrYukselUrun
ejcancer.com/article/S0959-8…
I DUBBI DI MARTA | Podcast
Le risposte della BCA alle domande delle pazienti
🔗tinyurl.com/4m5xj26t
🔊 24 - Cos'è l'immunoterapia e quando si usa nel tumore della mammella? Risponde @AlessiaRognone
#breastcancer #Immunotherapy
open.spotify.com/episode/7K2…
On-line nuovi materiali!
📚Confronto del valore prognostico e predittivo dell’espressione genica immuno relata vs infiltrato linfocitario tumorale nel ca. mammario HER2+ in stadio precoce - A cura di Z. Ballatore (AN)
tinyurl.com/2nsrysex
jamanetwork.com/journals/jam…
@JAMAOnc